Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab MRI study in RRMS
NCT01395316Phase 4Completed
- Sponsor
- University of Chicago
- Start
- Jun 2011
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by University of Chicago. Started Jun 2011; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01395316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395316.